Cyclophilin A as a potential genetic adjuvant to improve HIV-1 Gag DNA vaccine immunogenicity by eliciting broad and long-term Gag-specific cellular immunity in mice

References

• Riviere Y, McChesney MB, Porrot F, Tanneau-Salvadori F, Sansonetti P, Lopez O, Pialoux G, Feuillie V, Mollereau M, Chamaret S, et al. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 1995; 11:903-7; PMID:7492437; http://dx.doi.org/10.1089/aid.1995.11.903
   PubMed Web of Science ®Google Scholar
• Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, Miedema F. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J Infect Dis 1998; 178:1008-18; PMID:9806028; http://dx.doi.org/10.1086/515659
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278:1447-50; PMID:9367954; http://dx.doi.org/10.1126/science.278.5342.1447
   PubMed Web of Science ®Google Scholar
• Ranasinghe S, Flanders M, Cutler S, Soghoian DZ, Ghebremichael M, Davis I, Lindqvist M, Pereyra F, Walker BD, Heckerman D, et al. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol 2012; 86:277-83; PMID:22031937; http://dx.doi.org/10.1128/JVI.05577-11
   PubMed Web of Science ®Google Scholar
• Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53; PMID:17173051; http://dx.doi.org/10.1038/nm1520
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Walker BD. HIV type 1-specific helper T cells: a critical host defense. AIDS Res Hum Retroviruses 1998; 14 Suppl 2:S143-7; PMID:9672231
   PubMedGoogle Scholar
• Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, Cohen D, Robbins GK, Pae E, Alter G, et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 2004; 200:701-12; PMID:15381726; http://dx.doi.org/10.1084/jem.20041270
   PubMed Web of Science ®Google Scholar
• Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, McCutchan F, Njovu L, Geis S, Hoffmann O, Maboko L, et al. CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol 2007; 81:2440-8; PMID:17182686; http://dx.doi.org/10.1128/JVI.01847-06
   PubMed Web of Science ®Google Scholar
• Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994; 372:359-62; PMID:7969494; http://dx.doi.org/10.1038/372359a0
   PubMed Web of Science ®Google Scholar
• Thali M, Bukovsky A, Kondo E, Rosenwirth B, Walsh CT, Sodroski J, Gottlinger HG. Functional association of cyclophilin A with HIV-1 virions. Nature 1994; 372:363-5; PMID:7969495; http://dx.doi.org/10.1038/372363a0
   PubMed Web of Science ®Google Scholar
• Gamble TR, Vajdos FF, Yoo S, Worthylake DK, Houseweart M, Sundquist WI, Hill CP. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 1996; 87:1285-94; PMID:8980234; http://dx.doi.org/10.1016/S0092-8674(00)81823-1
   PubMed Web of Science ®Google Scholar
• Braaten D, Ansari H, Luban J. The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein. J Virol 1997; 71:2107-13; PMID:9032343
   PubMed Web of Science ®Google Scholar
• Zhao Y, Chen Y, Schutkowski M, Fischer G, Ke H. Cyclophilin A complexed with a fragment of HIV-1 gag protein: insights into HIV-1 infectious activity. Structure 1997; 5:139-46; PMID:9016720; http://dx.doi.org/10.1016/S0969-2126(97)00172-X
   PubMed Web of Science ®Google Scholar
• Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 2010; 467:214-7; PMID:20829794; http://dx.doi.org/10.1038/nature09337
   PubMed Web of Science ®Google Scholar
• Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008; 46:1769-81; PMID:18433307; http://dx.doi.org/10.1086/587993
   PubMed Web of Science ®Google Scholar
• Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194:1638-49; PMID:17109335; http://dx.doi.org/10.1086/509258
   PubMed Web of Science ®Google Scholar
• McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-905; PMID:19012957; http://dx.doi.org/10.1016/S0140-6736(08)61592-5
   PubMed Web of Science ®Google Scholar
• Yu H, Tawab-Amiri A, Dzutsev A, Sabatino M, Aleman K, Yarchoan R, Terabe M, Sui Y, Berzofsky JA. IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses. J leukoc Biol 2011; 90:205-14; PMID:21474552; http://dx.doi.org/10.1189/jlb.1010579
   PubMed Web of Science ®Google Scholar
• Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, Berzofsky JA. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Investig 2010; 120:607-16; PMID:20101095; http://dx.doi.org/10.1172/JCI39293
   PubMed Web of Science ®Google Scholar
• Terabe M, Tagaya Y, Zhu Q, Granger L, Roederer M, Waldmann TA, Berzofsky JA. IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells. J Immunol 2008; 180:7276-86; http://dx.doi.org/10.4049/jimmunol.180.11.7276
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Talbott KT, Cress C, Ferraro B, Tuyishme S, Mallilankaraman K, Cisper NJ, Morrow MP, Wu SJ, Kawalekar OU, et al. A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge. Vaccine 2011; 29:6755-62; PMID:21238574; http://dx.doi.org/10.1016/j.vaccine.2010.12.064
   PubMed Web of Science ®Google Scholar
• Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N, Weiner DB. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009; 113:5868-77; PMID:19304955; http://dx.doi.org/10.1182/blood-2008-11-190520
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. J Clin Investig 2004; 114:1241-4; PMID:15520855; http://dx.doi.org/10.1172/JCI23467
   PubMed Web of Science ®Google Scholar
• Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, Khan WN, Kornbluth RS, Stone GW. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine 2012; 30:691-702; PMID:22146759; http://dx.doi.org/10.1016/j.vaccine.2011.11.088
   PubMed Web of Science ®Google Scholar
• Arruda LB, Sim D, Chikhlikar PR, Maciel M, Jr., Akasaki K, August JT, Marques ET. Dendritic cell-lysosomal-associated membrane protein (LAMP) and LAMP-1-HIV-1 gag chimeras have distinct cellular trafficking pathways and prime T and B cell responses to a diverse repertoire of epitopes. J Immunol 2006; 177:2265-75; http://dx.doi.org/10.4049/jimmunol.177.4.2265
   PubMed Web of Science ®Google Scholar
• Chikhlikar P, Barros de Arruda L, Agrawal S, Byrne B, Guggino W, August JT, Marques ET, Jr. Inverted terminal repeat sequences of adeno-associated virus enhance the antibody and CD8(+) responses to a HIV-1 p55Gag/LAMP DNA vaccine chimera. Virology 2004; 323:220-32; PMID:15193918; http://dx.doi.org/10.1016/j.virol.2004.02.025
   PubMed Web of Science ®Google Scholar
• Chikhlikar P, Barros de Arruda L, Maciel M, Silvera P, Lewis MG, August JT, Marques ET. DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques. PloS one 2006; 1:e135; PMID:17205139; http://dx.doi.org/10.1371/journal.pone.0000135
   PubMedGoogle Scholar
• de Arruda LB, Chikhlikar PR, August JT, Marques ET. DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology 2004; 112:126-33; PMID:15129672; http://dx.doi.org/10.1111/j.1365-2567.2004.01823.x
   PubMed Web of Science ®Google Scholar
• Marques ET, Jr., Chikhlikar P, de Arruda LB, Leao IC, Lu Y, Wong J, Chen JS, Byrne B, August JT. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J Biol Chem 2003; 278:37926-36; PMID:12824194; http://dx.doi.org/10.1074/jbc.M303336200
   PubMed Web of Science ®Google Scholar
• Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 2002; 16:135-44; PMID:11825572; http://dx.doi.org/10.1016/S1074-7613(02)00259-5
   PubMed Web of Science ®Google Scholar
• Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474:658-61; PMID:21720370; http://dx.doi.org/10.1038/nature10195
   PubMed Web of Science ®Google Scholar
• Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474:654-7; PMID:21613998; http://dx.doi.org/10.1038/nature10117
   PubMed Web of Science ®Google Scholar
• Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, Fuller JC, Jackson RM, Lamb T, Briggs TA, et al. Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 2009; 41:829-32; PMID:19525956; http://dx.doi.org/10.1038/ng.373
   PubMed Web of Science ®Google Scholar
• Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cimarelli A. With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). Gene Therapy 2006; 13:991-4; PMID:16525481; http://dx.doi.org/10.1038/sj.gt.3302753
   PubMed Web of Science ®Google Scholar
• Hou J, Liu Y, Shao Y. The MSHA Strain of Pseudomonas Aeruginosa Activated TLR Pathway and Enhanced HIV-1 DNA Vaccine Immunoreactivity. PloS one 2012; 7:e47724; PMID:23077664; http://dx.doi.org/10.1371/journal.pone.0047724
   PubMedGoogle Scholar